Venetoclax (brand name: Venclexta), also translated as Weinaiteke, is an oral targeted anticancer agent designed to inhibit the B-cell lymphoma-2 (BCL-2) protein. It is primarily indicated for the treatment of hematological malignancies.

AccuSift provides high-performance competitive antibody pairs for venetoclax detection. These reagents offer exceptional inter-batch consistency and are optimized specifically for IVD kit development, including lateral flow assays, chemiluminescence, ELISA, and POCT platforms. Featuring high affinity and high specificity, they enable rapid and reliable detection.

Sensitivity: ELISA LOD: 0.05 μg/mL